株式会社MBR



References

<SMP-105(BCG-CWS)>

SMP-105

1)

Uenishi Y, Okada T, Okabe S, Sunagawa M: Study on the cell wall skeleton derived from Mycobacterium bovis BCG Tokyo (SMP-105): Establishment of preparation and analytical methods. Chem Pharm Bull 55, 843-852, 2007.

2)

Uenishi Y, Fujita Y, Kusunose N, Yano I, Sunagawa M: Comprehensive analysis of mycolic acid subclass and molecular species composition of Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105). J Microbiol Methods 72, 149-156, 2008

3)

Murata M: Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci 99, 1435-1440, 2008

4)

Kashiwazaki Y, Murata M, Sato T, Miyauchi M, Nakagawa M, Fukushima A, Chiba N, Azuma I, Yamaoka Y: Injection of cell-wall skeleton of Mycobacterium bovis BCG draining to a sentinel lymph node eliminates both lymph node metastases and the primary transplanted tumor. Drug Discov Ther 2, 168-177, 2008

5)

Kashiwazaki Y, Murata M, Fujii T, Nakagawa M, Fukushima A, Chiba N, Azuma I, Yamaoka T: Immune response against cell-wall skeleton of Mycobacterium bovis BCG at the inoculation site and peripheral lymphoid organs. Drug Discov Ther 2, 178-187, 2008

 6) Uenishi Y, Kawabe K, Nomura T, Nakai M, Sunagawa M: Morphological study on Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105). J Microbiol Methods. 2009 May; 77(2): 139-144. Epub 2009 Feb 1.
 7) Uenishi Y, Takii T, Yano I, Sunagawa M: Separation and molecular characterization of mycolic acid from the cell wall skelton of Mycobacterium bovis BCG Tokyo 172 (SMP-105) and BCG substrains by normal-phase highperformance liquid chromatography and liquid chromatography/mass spectrometry. J. Microbiol Methods. 2009 Jun; 77(3):320-322, Epub 2009 Mar 27. 
 8) Uenishi Y, Kusunose N, Yano I,Sunagawa M: Isolation and idntification of arabinose mycolates of Cell Wall Skelton (CWS) derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105). J Microbiol Methods. 2010 Mar; 80(3): 302-305, Epub 2010 Jan15. 

BCG-CWSの基礎研究

9)

Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K, Seya T: Maturation of Human Dendritic Cells by Cell Wall Skeleton of Mycobacterium bovis Bacillus Calmette-Gue´rin: Involvement of Toll-Like Receptors. Infect Immun 68, 6883-6890, 2000

10)

Nakajima H, Kawasaki K, Oka Y, et al.: WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immnother 53, 617-624, 2004

11)

Akazawa T, Masuda H, Saeki Y, Matsumoto M, Takeda K, Tsujimura K, Kuzushima K, Takahashi T, Azuma I, Akira S, Toyoshima K, Seya T: Adjuvant-Mediated Tumor Regression and Tumor-Specific Cytotoxic Response Are Impaired in MyD88-Deficient Mice. Cancer Res 64, 757-764, 2004

 12) Miyauchi M, Murata M, Shibuya K, Koga-Yamakawa E. Yanagawa Y, Azuma I, Kashiwazaki Y: Phagocytosis plays a dual role in activating dendritic cells; digestive production of active Toll-like receptor ligands and cooperation with Toll-like receptor signaling. Drug Discoveries & Therapeutics 4(2), 135-143, 2010 

BCG-CWSの臨床研究

13)

Yamamura Y, Ogura T, Yoshimoto T, et al.: Successful treatment of the patients with malignant pleural effusion with BCG cell-wall skeleton. Gunn 67, 669-677, 1976.

14)

Yasumoto K, Manabe H, Ueno M, et al.: Immunotherapy of human lung cancer with BCG cell-wall skeleton. Gunn 67, 787-795, 1976.

15)

Yamamura Y, Sakatani M, Ogura T, Azuma I: Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS). Cancer 43, 1314-1319, 1979.

16)

Ochiai T, Sato H, Hayashi R: Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial. Cancer Immunol Immunother 14, 167-171, 1983

17)

Ikegami H, Horai T, Hattori S: Combined modality studies on small cell carcinoma of the lung ? current status in Japan. Recent Results Cancer Res 76, 257-266, 1981.

18)

Hayashi A: Interferon-γ as a marker for the effective cancer immunotherapy with BCG-cell wall skeleton. Proc Japan Acad 70, 205-209, 1994.

19)

Hayashi A, Noda A: Does the cell wall skeleton from Baccille Calmette-Guerin directly induce interferon-γ, independent of interleukin-12? Jpn J Clin Oncol 26, 124-127, 1996.

20)

Hayashi A, Doi O, Azuma I, Toyoshima K: Immuno-friendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patients. Proc Japan Acad 74, 50-55, 1998.

21)

林 昭: よみがえったBCG-CWS. 医学のあゆみ 別冊 415-421, 2002.

22)

林 昭: Dendritic cell-cell based immunotherapy using BCG-CWS alone: Outstanding clinical effect and the role of peripheral lymph nodes. A Handout distributed in the 36th Annual Meeting (2006) of Japanese Society for Immunology

23)

児玉 憲, 瀬谷 司: Toll-like receptorとがん免疫療法. Biotherapy 17, 490-493, 2003.

 24) Kodama K, Higashiyama M, Takami K, Oda K, Okami J, Maeda J, Akazawa T, Matsumoto M, Seya T, Wada M, Toyoshima K: Innate immune therapy with a Bacillus Calmette-Guerin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study. Surg Today 39, 194-200, 2009 
 25) Hayashi A, Nishida Y, Yoshii S, Seo Y Kim, Uda H, Hamasaki T: Immunotherapy of ovarian cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin: Effect of lymphadenectomy. Cancer Sci 100, 1991-1995, 2009.

最新の免疫学について

26)

Abbas A.K., Lichtman A.H.: 基礎免疫学、免疫システムの機能とその異常、原著第2版、2006-2007最新版、エルゼビア・ジャパン 

27)

Janeway C.A.Jr., Travers P., Walport M., Shlomchik M.J.:免疫生物学、免疫系の正常と病理、原著第5版、南江堂
 28) 岸本忠三、中嶋彰:新現代免疫物語「抗体医薬」と「自然免疫」の驚異、講談社ブルーバックス 
 

<MBR-108(SM-108)>

SM-108の基礎研究

1)

Fukui M, Inaba M, Tsukagoshi S, et al.: New antitumor imidazole derivative, 5-carbamoyl-1H-imidazol-4-yl peperonylate, as an inhibitor of purine synthesis and its activation by adenine phsophoribosyltransferase. Cancer Res 42, 1098-1102, 1982.

2)

Inaba M, Fukui M, Yoshida N, et al.: Collateral sensitivity of 6-mercaptopurine-resistant sublines of P388 and L1210 to the new purine antagonists, 5-carbamoyl-1H-imidazol-4-yl peperonylate and 4-carbamoylimidazolium-5-olate. Cancer Res 42, 1103-1106, 1982.

3)

Yoshida N, Nakamura M, Fukui M, et al.: Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors. Cancer Res 43, 5851-5856, 1983.

4)

中村 誠, 福井 優, 森貞 信也ら: 4-Carbamoylimidazolium-5-olate(SM-108)の経口投与による抗腫瘍効果. 癌と化学療法 12, 2030-2036, 1985.

5)

Terai C, Hakoda M, Yamanaka H, et al.: Differential cytotoxic effects of mizoribine and its aglycone on human and murine cells and on normal and enzyme-deficient human cells. Biochem. Pharmacol. 50, 1099-1102, 1995.

SM-108の臨床試験

6)

宇塚 善郎, 斉藤 淑子: SM-108. 最新医学 41, 519-527, 1986.

7)

西川 政勝, 森田 孝一, 関根 隆夫ら: SM-108による慢性骨髄増殖性疾患の治療経験. 癌と化学療法 14, 3078-3082, 1987.

8)

宇塚 善郎, 斉藤 淑子: 造血幹細胞動態よりみた前白血病状態の治療 −SM-108−. 癌と化学療法 15, 1215-1222, 1988.

9)

木村 禧代二, 鈴置 洋三, 小川 一誠ら: SM-108(4-Carbamoylimidazolium-5-olate)のPhase I Studyならびに肺癌を対象とした初期Phase II Study. と化学療法 16, 113-121, 1989

10)

木村 禧代二, 山田 一正, 宇塚 善郎ら: 造血器腫瘍に対するSM-108(4-Carbamoylimidazolium-5-olate)のphase II study. 癌と化学療法 16, 123-130, 1989.

 

<抗酸菌の研究 その他>
 1) Kawamura Y, Tomida J, Morita Y, Naka T, Mizuno S, Fujiwara N: 'Lysobacter enzymogenes ssp.cookii' Christensen1978 should be recognized as an independent species, Lysobacter cookii sp.nov. FEMS Microniology Letter, 298, 118-123, 2009 
 2) Naka T, Nakata N, Maeda S, Yamamoto R, Doe M, Mizuno S, Niki M, Kobayashi K, Ogura H, Makino M, and Fujiwara N: The structure and host recognition of serotype 13 glycopeptidolipid from Mycobacterium intracellulare. J. Bacteriology 193, 5766-5774, 2011. 
 3) Naka T, Maeda S, Niki M, Ohara N, Yamamoto S, Yano I, Maeyama J, Ogura H, Kobayashi K, and Fujiwara N: The lipid phenotype of two distinct subpopulations of Mycobacterium bovis Bacillus Calmette-Guerin Tokyo 172 substrain, J. Biological Chemistry 286, 44153-44161, 2011. 
 4) Fijiwara N, Naka T, Ogawa M, Yamamoto R, Ogura H, and Taniguchi H: Characteristics of Mycobacterium smegmatis J15cs strain lipids, Tuberculosis 92, 187-192, 2012 


Copyright 2009 MBR Co., Ltd. All Rights Reserved.